Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$890.51 USD

890.51
1,121,461

+6.03 (0.68%)

Updated Oct 2, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

    LLY vs. NVO: Which Stock Is the Better Value Option?

    LLY vs. NVO: Which Stock Is the Better Value Option?

      Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

      Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

        Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

        Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

          Tirthankar Chakraborty headshot

          The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

          The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

            Mark Vickery headshot

            Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

            Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK).

              J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

              The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

                Mark Vickery headshot

                Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

                Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).

                  Pfizer to Defer Price Increases After Discussion With Trump

                  Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.

                    Biogen's Alzheimer Disease Candidate Succeeds in Phase II

                    Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

                      Is Pfizer's Price Hike an Effect of Drug Policy on Sector?

                      Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.

                        Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

                        Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.

                          Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study

                          Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).

                            Nitish Marwah headshot

                            Will a Trade War With China Wreak Havoc in US Healthcare?

                            It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

                              The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern

                              The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern

                                Mark Vickery headshot

                                Top Research Reports for Amazon, Intel & Eli Lilly

                                Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Intel (INTC) and Eli Lilly (LLY).

                                  Merck's Keytruda Under FDA Review for Advanced Melanoma

                                  Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.

                                    Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

                                    Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.

                                      Merck (MRK) Presents New Data from Januvia Diabetes Studies

                                      Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

                                        Lilly Wins Favorable Ruling From U.S. Court in Alimta Row

                                        Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.

                                          Merck (MRK) Stock Up So Far This Year on Keytruda Strength

                                          Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

                                            Incyte (INCY) Announces Positive Results on Jakafi for GVHD

                                            Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

                                              Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

                                              Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

                                                LLY vs. NVO: Which Stock Should Value Investors Buy Now?

                                                LLY vs. NVO: Which Stock Is the Better Value Option?

                                                  Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

                                                  Is Eli Lilly and Company (LLY) Outperforming Other Medical Stocks This Year?